Endo International (Endo International) GF Value : $0.23 (As of May. 06, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Endo International GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-06), Endo International's share price is $0.0006. Endo International's GF Value is $0.23. Therefore, Endo International's Price-to-GF-Value for today is 0.00.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Endo International is Possible Value Trap, Think Twice.

Endo International (OTCPK:ENDPQ) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Endo International's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.0006	/	0.23
	=	0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endo International GF Value Related Terms

Thank you for viewing the detailed overview of Endo International's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Endo International (Endo International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo International PLC (OTCPK:ENDPQ) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

EO7:Germany

Address

Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4

Website

https://www.endo.com

Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.

Executives

James Patrick Tursi	officer: Executive VP, Global R&D	106 ASHLEY COURT, MOORESTOWN NJ 08057
Frank B. Raciti	officer: VP, Controller and CAO	C/O ENDO HEALTH SOLUTIONS INC., 1400 ATWATER DRIVE, MALVERN PA 19355
Shane Cooke	director	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
William P Montague	director
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
George Apostol	officer: EVP, Head of Global R&D	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN 4 L2 00000
Mary Christine Smith	director	3658 50TH AVE NE, SEATTLE WA 98105
Mark T. Bradley	officer: EVP, Chief Financial Officer	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Mark G Barberio	director	19 WIK STREET, WILLIAMSVILLE NY 14221
Jack D. Boyle	officer: SVP, Interim Controller	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Roger H Kimmel	director	LATHAM & WATKINS, 885 THIRD AVENUE, NEW YORK NY 10022
Domenico Ciarico	officer: EVP & Chief Commercial Officer	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Rahul Garella	officer: EVP, Intl Pharmaceuticals	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Carrie Ann Nichol	officer: VP, Controller & CAO	927 GRANDVIEW DRIVE, EXTON PA 19341